Printer Friendly

Articles from M2 Pharma (May 22, 2019)

1-24 out of 24 article(s)
Title Author Type Words
Catalent completes Paragon Bioservices acquisition. 514
Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca in Advanced Ovarian Cancer. 900
Corvidia Therapeutics names new director. 224
Genomind Launches Genetics-Based Mental Health Test Genomind Professional PGx. 281
Halozyme expands collaboration and license agreement with argenx. 239
LineaRx Anticipates Expansion in Diagnostics Market via Follow-on Order and New Linear DNA Amplicons for Additional Assay. 328
Mallinckrodt names new director. 277
Mallinckrodt welcomes Carlos V. Paya, MD, PhD to board. 168
Merck to acquire Peloton Therapeutics for purchase price of USD1.05bn upfront. 197
Merritt Healthcare to construct USD10.2m Mount Sinai outpatient development project in Manhattan. 210
New trial data reveals effectiveness of AstraZeneca's Symbicort Turbuhaler. 225
NightWare awarded US FDA breakthrough status for NightWare for Post-Traumatic Stress Disorder (PTSD). 248
Ocular Therapeutix Releases Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma. 510
OncoSec Medical Incorporated proposes public offering of units. 132
Perrigo wins US FDA final approval for AB rated generic Voltaren Gel 1%. 208
Phase III Study Shows Nintedanib Slows Loss of Pulmonary Function in People Living with Systemic Sclerosis Associated ILD1. 493
PolyPid Ltd awarded US FDA second QIDP designation for D-PLEX100 for prevention of post-abdominal surgery incisional infection. 256
Rainier Therapeutics Presents Patient Biopsy Data Demonstrating Vofatamab's Ability to Increase Immune Cell Activation. 360
Second-Generation Blood Test for Irritable Bowel Syndrome Validated as Providing Most Conclusive Diagnosis of Inclusion for IBS. 480
Selvita incurs higher net loss of USD2.2m in Q1 2019. Financial report 232
SpringWorks Therapeutics doses first patient in phase three nirogacestat 'DeFi' trial. 216
US Food and Drug Administration Accepts Sesen Bio's Analytical Comparability Plan to Support the BLA and Commercialisation of Its Lead Asset, Vicinium for Non-Muscle Invasive Bladder Cancer. 582
US Merck Provides Update on Phase 3 KEYNOTE-119 Study of Keytruda Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer. 437
Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week. 681

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters